IBD途径:从患者的角度

M. Barker, Rugina Ali
{"title":"IBD途径:从患者的角度","authors":"M. Barker, Rugina Ali","doi":"10.33590/emj/10310701","DOIUrl":null,"url":null,"abstract":"The emergence of anti-TNF biosimilars has had significant implications for the biologic treatment of inflammatory bowel disease (IBD). Significant cost savings provide an incentive for healthcare providers to encourage the prescription of biosimilars instead of reference products. However, patients may have concerns about the switching process, the reason for the switch, or the biosimilar itself, and it is important for healthcare professionals (HCP) to take these into account to enable an informed, shared treatment decision.\n\nThe aim of this symposium was to understand treatment of IBD from the patient’s perspective, especially when switching treatment to a biosimilar product. Beginning with a review of the current and future treatment landscapes, the implications of the increasing availability of biosimilars were discussed. The role of HCP in communicating information about the switch was explored by the multidisciplinary faculty who also compared switching practices at their own treatment centres and shared best practices. Alongside videos of interviews with patients who had undergone a switch to a biosimilar, a patient advocacy perspective was provided by Ms Luisa Avedano, CEO, the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA).","PeriodicalId":92504,"journal":{"name":"EMJ. Gastroenterology","volume":"18 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The IBD Pathway: From a Patient Perspective\",\"authors\":\"M. Barker, Rugina Ali\",\"doi\":\"10.33590/emj/10310701\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The emergence of anti-TNF biosimilars has had significant implications for the biologic treatment of inflammatory bowel disease (IBD). Significant cost savings provide an incentive for healthcare providers to encourage the prescription of biosimilars instead of reference products. However, patients may have concerns about the switching process, the reason for the switch, or the biosimilar itself, and it is important for healthcare professionals (HCP) to take these into account to enable an informed, shared treatment decision.\\n\\nThe aim of this symposium was to understand treatment of IBD from the patient’s perspective, especially when switching treatment to a biosimilar product. Beginning with a review of the current and future treatment landscapes, the implications of the increasing availability of biosimilars were discussed. The role of HCP in communicating information about the switch was explored by the multidisciplinary faculty who also compared switching practices at their own treatment centres and shared best practices. Alongside videos of interviews with patients who had undergone a switch to a biosimilar, a patient advocacy perspective was provided by Ms Luisa Avedano, CEO, the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA).\",\"PeriodicalId\":92504,\"journal\":{\"name\":\"EMJ. Gastroenterology\",\"volume\":\"18 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-06-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EMJ. Gastroenterology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33590/emj/10310701\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EMJ. Gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33590/emj/10310701","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

抗肿瘤坏死因子生物类似药的出现对炎症性肠病(IBD)的生物治疗具有重要意义。显著的成本节约为医疗保健提供者提供了鼓励处方生物仿制药而不是参考产品的激励。然而,患者可能会对转换过程、转换原因或生物仿制药本身有顾虑,医疗保健专业人员(HCP)必须考虑到这些因素,以实现知情的、共享的治疗决策。本次研讨会的目的是从患者的角度了解IBD的治疗,特别是当治疗转向生物仿制药产品时。首先回顾了当前和未来的治疗前景,讨论了生物仿制药日益增加的可用性的影响。多学科教师探讨了HCP在交流转换信息中的作用,他们还比较了各自治疗中心的转换实践,并分享了最佳实践。欧洲克罗恩病和溃疡性结肠炎协会联合会(EFCCA)首席执行官Luisa Avedano女士除了提供了对转向生物仿制药患者的访谈视频外,还提供了患者倡导观点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The IBD Pathway: From a Patient Perspective
The emergence of anti-TNF biosimilars has had significant implications for the biologic treatment of inflammatory bowel disease (IBD). Significant cost savings provide an incentive for healthcare providers to encourage the prescription of biosimilars instead of reference products. However, patients may have concerns about the switching process, the reason for the switch, or the biosimilar itself, and it is important for healthcare professionals (HCP) to take these into account to enable an informed, shared treatment decision. The aim of this symposium was to understand treatment of IBD from the patient’s perspective, especially when switching treatment to a biosimilar product. Beginning with a review of the current and future treatment landscapes, the implications of the increasing availability of biosimilars were discussed. The role of HCP in communicating information about the switch was explored by the multidisciplinary faculty who also compared switching practices at their own treatment centres and shared best practices. Alongside videos of interviews with patients who had undergone a switch to a biosimilar, a patient advocacy perspective was provided by Ms Luisa Avedano, CEO, the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA).
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
审稿时长
19 weeks
期刊最新文献
UEG 2023 Interview: Patrizia Burra Challenges in Management of Immune Checkpoint Inhibitor-Associated Hepatitis Preventive Medicine in Gastroenterology Severe, Refractory Anaemia Associated with Helicobacter Pylori Infection Managed With L. Reuteri DSMZ17648 (Probiotic) and Haeme Iron Supplements: A Case Report A Rare Complication of Valproate-Induced Acute Pancreatitis in an Adult Patient with Bipolar Disorder: A Case Report
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1